Immuneering Corporation
IMRX
Rank in Stocks
#15941
Immuneering Corporation is a biopharmaceutical company dedicated to developing... Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Share Price
$3.65
Last synced: 2026-11-09
Market Cap
$236.39M
Change (1 day)
-0.82%
Change (1 year)
-45.85%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Immuneering Corporation (IMRX)
Category
Healthcare
Operating Margin for Immuneering Corporation (IMRX)
Operating Margin as of November 2026 TTM: 0.00%
According to Immuneering Corporation's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Immuneering Corporation from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -16,325.77% | 902.09% |
| 2021 | -1,629.17% | 120.45% |
| 2020 | -739.01% | 125.51% |
| 2019 | -327.71% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Immuneering Corporation's operating margin
What was Immuneering Corporation's operating margin in 2025?
In 2025, Immuneering Corporation's operating margin was 0.00%, compared with 0.00% in 2024.
How has Immuneering Corporation's operating margin changed since 2020?
From 2020 to 2025, Immuneering Corporation's operating margin was highest in 2025 (0.00%) and lowest in 2022 (-16,325.77%).
How does Immuneering Corporation's operating margin compare with similar companies?
Immuneering Corporation's operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.